Impaired reproductive function and possible infertility are major concerns in long-term survivors of hematological malignancies. The ongoing increase in the survival rates of these patients is therefore accompanied with a growing demand for effective, safe and specifically tailored fertility preservation options. When approaching patients facing hematological malignancy, an individual evaluation of potential infertility risks and possible preventive or preserving measures should be performed. This review aims to provide up-to-date knowledge on female reproductive risks, and ovarian, uterine and genital injuries associated with therapy regimens currently used in hemato-oncological disorders. Recent progress in fertility preservation methods including ovarian tissue cryopreservation and transplantation, egg and embryo freezing, ovarian transposition and their specific role in hematological disorders are presented. The efficacy of these methods, possible risks and future challenges are critically discussed.

1.
Forman EJ, Anders CK, Behera MA: A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril 2010;94:1652-1656.
2.
Lee S, Heytens E, Moy F, Ozkavukcu S, Oktay K: Determinants of access to fertility preservation in women with breast cancer. Fertil Steril 2011;95:1932-1936.
3.
Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, Keefe DL, Albrecht TL: Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol 2009;27:5952-5957.
4.
Wallace WH, Kelsey TW: Human ovarian reserve from conception to the menopause. PLoS One 2010;5:e8772.
5.
Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA: Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368-2374.
6.
Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D: Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010;20:280-285.
7.
Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E: Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010;94:638-644.
8.
Senapati S, Morse CB, Sammel MD, Kim J, Mersereau JE, Efymow B, Gracia CR: Fertility preservation in patients with haematological disorders: a retrospective cohort study. Reprod Biomed Online 2014;28:92-98.
9.
Meirow D: Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123-131.
10.
Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y, Robison LL: Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-896.
11.
Critchley HO, Wallace WH: Do survivors of childhood cancer have increased incidence of premature menopause? Nat Clin Pract Oncol 2007;4:84-85.
12.
Wallace WH, Anderson RA, Irvine DS: Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-218.
13.
Brusamolino E, Lunghi F, Orlandi E, Astori C, Passamonti F, Barate C, Pagnucco G, Baio A, Franchini P, Lazzarino M, Bernasconi C: Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica 2000;85:1032-1039.
14.
Wallace WH, Thomson AB, Saran F, Kelsey TW: Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62:738-744.
15.
Lushbaugh CC, Casarett GW: The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976;37:1111-1125.
16.
Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R, Appelbaum FR: Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-3052.
17.
Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR: Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1989;1:75-79.
18.
Bath LE, Critchley HO, Chambers SE, Anderson RA, Kelnar CJ, Wallace WH: Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 1999;106:1265-1272.
19.
Critchley HO, Wallace WH, Shalet SM, Mamtora H, Higginson J, Anderson DC: Abdominal irradiation in childhood: the potential for pregnancy. Br J Obstet Gynaecol 1992;99:392-394.
20.
Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM: Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993;8:2080-2087.
21.
Oktem O, Oktay K: A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-10162.
22.
Nicosia SV, Matus-Ridley M, Meadows AT: Gonadal effects of cancer therapy in girls. Cancer 1985;55:2364-2372.
23.
Meirow D, Biederman H, Anderson RA, Wallace WH: Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 2010;53:727-739.
24.
Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D: Cyclophosphamide triggers follicle activation and ‘burnout': AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013;5:185ra162.
25.
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
26.
Harel S, Ferme C, Poirot C: Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica 2011;96:1692-1699.
27.
Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M: Long-term events in adult patients with clinical stage Ia-IIa nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487-6493.
28.
Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, Smith K, Schwartz A, Tsang RW, Crump M, Wells W, Sun A, Gospodarowicz MK: Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007;25:11-15.
29.
Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-7564.
30.
Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, Blumenfeld Z, Abraham A, Manor Y, Shpilberg O, Lishner M: Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:623-627.
31.
Seshadri T, Hourigan MJ, Wolf M, Mollee PN, Seymour JF: The effect of the hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leuk Res 2006;30:483-485.
32.
Grigg AP, McLachlan R, Zaja J, Szer J: Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000;26:1089-1095.
33.
Meirow D: Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999;33:65-76.
34.
Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF: Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998;22:989-994.
35.
Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R: Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998;21:287-290.
36.
Jadoul P, Donnez J: How does bone marrow transplantation affect ovarian function and fertility? Curr Opin Obstet Gynecol 2012;24:164-171.
37.
Nabhan SK, Bitencourt MA, Duval M, Abecasis M, Dufour C, Boudjedir K, Rocha V, Socie G, Passweg J, Goi K, Sanders J, Snowden J, Yabe H, Pasquini R, Gluckman E: Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica 2010;95:1783-1787.
38.
Borgmann-Staudt A, Rendtorff R, Reinmuth S, Hohmann C, Keil T, Schuster FR, Holter W, Ehlert K, Keslova P, Lawitschka A, Jarisch A, Strauss G: Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone Marrow Transplant 2012;47:271-276.
39.
Holm K, Nysom K, Brocks V, Hertz H, Jacobsen N, Muller J: Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. Bone Marrow Transplant 1999;23:259-263.
40.
Spinelli S, Chiodi S, Costantini S, Van Lint MT, Raiola AM, Ravera GB, Bacigalupo A: Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003;88:1163-1168.
41.
DeLord C, Treleaven J, Shepherd J, Saso R, Powles RL: Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant 1999;23:523-525.
42.
Yanai N, Shufaro Y, Or R, Meirow D: Vaginal outflow tract obstruction by graft-versus-host reaction. Bone Marrow Transplant 1999;24:811-812.
43.
Corson SL, Sullivan K, Batzer F, August C, Storb R, Thomas ED: Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol 1982;60:488-492.
44.
Hirokawa M, Sato H, Kawabata Y, Sawada K: Vaginal outflow tract obstruction associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation. Int J Hematol 2006;83:181-182.
45.
Chuah C: Imatinib does not impair gonadal function. Leuk Res 2012;36:262-263.
46.
Leader A, Lishner M, Michaeli J, Revel A: Fertility considerations and preservation in haemato-oncology patients undergoing treatment. Br J Haematol 2011;153:291-308.
47.
Gonfloni S: Modulating c-Abl nuclear activity as a strategy to preserve female fertility. Cell Cycle 2010;9:217-218.
48.
Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, Apperley JF: The effects of imatinib on pregnancy outcome. Blood 2008;111:5505-5508.
49.
Hensley ML, Ford JM: Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40:21-25.
50.
Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH: Anti-mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012;97:2059-2067.
51.
Anderson RA, Cameron DA: Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336-1343.
52.
Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E: Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007;22:1626-1633.
53.
Blumenfeld Z: How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-1054.
54.
Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM: Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-811.
55.
Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA: Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-319.
56.
Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, Petroff B: Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010;53:740-752.
57.
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-276.
58.
Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V, Engert A, Borchmann P: No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010;21:2052-2060.
59.
Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-2341.
60.
Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-538.
61.
Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M, Schmidt KT, Ernst E, Luyckx V, Andersen CY: Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril 2013;99:1503-1513.
62.
Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, Schiff E, Dor J: Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005;353:318-321.
63.
Anderson RA, Hindmarsh PC, Wallace WH: Induction of puberty by autograft of cryopreserved ovarian tissue in a patient previously treated for Ewing sarcoma. Eur J Cancer 2013;49:2960-2961.
64.
Ernst E, Kjaersgaard M, Birkebaek NH, Clausen N, Andersen CY: Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue. Eur J Cancer 2013;49:911-914.
65.
Chung K, Donnez J, Ginsburg E, Meirow D: Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril 2013;99:1534-1542.
66.
Meirow D, Baum M, Yaron R, Levron J, Hardan I, Schiff E, Nagler A, Yehuda DB, Raanani H, Hourvitz A, Dor J: Ovarian tissue cryopreservation in hematologic malignancy: ten years' experience. Leuk Lymphoma 2007;48:1569-1576.
67.
Rosendahl M, Schmidt KT, Ernst E, Rasmussen PE, Loft A, Byskov AG, Andersen AN, Andersen CY: Cryopreservation of ovarian tissue for a decade in Denmark: a view of the technique. Reprod Biomed Online 2011;22:162-171.
68.
Dittrich R, Lotz L, Keck G, Hoffmann I, Mueller A, Beckmann MW, van der Ven H, Montag M: Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil Steril 2012;97:387-390.
69.
Andersen CY, Rosendahl M, Byskov AG, Loft A, Ottosen C, Dueholm M, Schmidt KL, Andersen AN, Ernst E: Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008;23:2266-2272.
70.
Ernst E, Bergholdt S, Jorgensen JS, Andersen CY: The first woman to give birth to two children following transplantation of frozen/thawed ovarian tissue. Hum Reprod 2010;25:1280-1281.
71.
Stern CJ, Gook D, Hale LG, Agresta F, Oldham J, Rozen G, Jobling T: First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod 2013;28:2996-2999.
72.
Abir R, Feinmesser M, Yaniv I, Fisch B, Cohen IJ, Ben-Haroush A, Meirow D, Felz C, Avigad S: Occasional involvement of the ovary in Ewing sarcoma. Hum Reprod 2010;25:1708-1712.
73.
Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J: Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010;116:2908-2914.
74.
Greve T, Clasen-Linde E, Andersen MT, Andersen MK, Sorensen SD, Rosendahl M, Ralfkiaer E, Andersen CY: Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells. Blood 2012;120:4311-4316.
75.
Kim SS, Radford J, Harris M, Varley J, Rutherford AJ, Lieberman B, Shalet S, Gosden R: Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod 2001;16:2056-2060.
76.
Meirow D, Ben Yehuda D, Prus D, Poliack A, Schenker JG, Rachmilewitz EA, Lewin A: Ovarian tissue banking in patients with Hodgkin's disease: is it safe? Fertil Steril 1998;69:996-998.
77.
Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra'anani H, Slyusarevsky E, Amariglio N, Schiff E, Rechavi G, Nagler A, Ben Yehuda D: Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 2008;23:1007-1013.
78.
Rosendahl M, Andersen MT, Ralfkiaer E, Kjeldsen L, Andersen MK, Andersen CY: Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010;94:2186-2190.
79.
Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, Anderson M, Schmidt KT, Andersen CY: Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril 2011;95:2158-2161.
80.
Dolmans MM, Jadoul P, Gilliaux S, Amorim CA, Luyckx V, Squifflet J, Donnez J, Van Langendonckt A: A review of 15 years of ovarian tissue bank activities. J Assist Reprod Genet 2013;30:305-314.
81.
Bastings L, Beerendonk CC, Westphal JR, Massuger LF, Kaal SE, van Leeuwen FE, Braat DD, Peek R: Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update 2013;19:483-506.
82.
Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K, Burnett AK: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27:3650-3658.
83.
Huang M, Li C, Liang H, Zhou J, Deng J, Liu W: Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 chromosomal translocations in hematologic malignancies. J Huazhong Univ Sci Technolog Med Sci 2006;26:661-663.
84.
Janse F, Donnez J, Anckaert E, de Jong FH, Fauser BC, Dolmans MM: Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment. J Clin Endocrinol Metab 2011;96:1136-1144.
85.
Donnez J, Silber S, Andersen CY, Demeestere I, Piver P, Meirow D, Pellicer A, Dolmans MM: Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births. Ann Med 2011;43:437-450.
86.
Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-Madrid B, van Langendonckt A: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-1410.
87.
Pfeifer S, Goldberg J, McClure R, Lobo R, Thomas M, Widra E, Licht M, Collins J, Cedars M, Racowsky C, Vernon M, Davis O, Gracia C, Catherino W, Thornton K, Rebar R, La Barbera A: Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37-43.
88.
Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM: Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;5:CD001750.
89.
Nayak SR, Wakim AN: Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril 2011;96:e51-e54.
90.
Von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T: Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009;92:1360-1365.
91.
Meirow D, Schiff E: Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr 2005;21-25.
92.
Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R: Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol 2010;30:566-572.
93.
Kujjo LL, Chang EA, Pereira RJ, Dhar S, Marrero-Rosado B, Sengupta S, Wang H, Cibelli JB, Perez GI: Chemotherapy-induced late transgenerational effects in mice. PLoS One 2011;6:e17877.
94.
Winther JF, Boice JD Jr, Mulvihill JJ, Stovall M, Frederiksen K, Tawn EJ, Olsen JH: Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a population-based study. Am J Hum Genet 2004;74:1282-1285.
95.
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K: Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510.
96.
Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M: Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril 2010;94:2871-2873.
97.
Robertson AD, Missmer SA, Ginsburg ES: Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril 2011;95:588-591.
98.
Noyes N, Porcu E, Borini A: Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 2009;18:769-776.
99.
Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA: Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet 2010;27:491-494.
100.
Demirtas E, Elizur SE, Holzer H, Gidoni Y, Son WY, Chian RC, Tan SL: Immature oocyte retrieval in the luteal phase to preserve fertility in cancer patients. Reprod Biomed Online 2008;17:520-523.
101.
Maman E, Meirow D, Brengauz M, Raanani H, Dor J, Hourvitz A: Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril 2011;95:64-67.
102.
In vitro maturation: a committee opinion. Fertil Steril 2013;99:663-666.
103.
Chian RC, Uzelac PS, Nargund G: In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 2013;99:1173-1181.
104.
Kiserud CE, Fosså A, Holte H, Fosså SD: Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 2007;96:1442-1449.
105.
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z: Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347-4353.
106.
Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F: Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 2009;91(suppl 4):1476-1478.
107.
Quintero RB, Helmer A, Huang JQ, Westphal L: Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 2010;93:865-868.
108.
Domingo J, Guillén V, Ayllón Y, Martínez M, Muñoz E, Pellicer A, Garcia-Velasco JA: Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 2012;97:930-934.
109.
Meirow D: Reproductive outcome after fertility preservation in girls and women. Hum Reprod 2013;28(suppl 1): i17-i18.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.